

VOLUME 74, 2003 KEYWORD INDEX

- Acoustic startle, 1
ACTH, 433
Activity, 87
Adaptation, 609
Addiction, 119, 635
Adenosine, 111
Adenosine deaminase, 111
 α_2 -Adrenoceptor antagonist, 663
 $\alpha_3\beta_4$ nicotinic receptor, 803
Adrenocortical activity, 649
Adult male rat, 649
Alcohol, 381
Alcohol abuse, 381
Alcohol dependence, 381
Alcohol use disorders, 381
Alcohol-nonpreferring rats, 335
Alcohol-preferring rats, 335
Alcohol-sensitivity, 21
Alcoholic beverages, 381
Alcoholism, 381
Amino acid transmitters, 21
 γ -Aminobutyric acid, 343
 γ -Aminobutyric acid (GABA), 21
4-Aminopyridine, 465
Ammonia, 523
AMPA, 389, 657
AMPA/kainate receptor antagonists, 595
Amphetamine, 529, 635
Amygdala kindling, 565
Anabolic steroids, 119
Analgesia, 149
Androgens, 119
Animal model of depression, 259
Anorexia, 505
Antagonists, 371
Anticonvulsant, 111
Antiepileptic, 221
Antinociception, 149, 465, 529, 603
Antipsychotic agents, 811
Antipsychotic test, 811
Antipsychotics, 11
Anxiety, 395, 609, 649
Anxiolytic tests, 11
Apamin, 465
Apomorphine, 205
Apyrase, 181
Aricept, 213
Atropine, 603
Attenuated response, 401
Audiogenic seizures, 595
Auditory perception, 287
Autoradiography, 335

Baboon, 287
Behavior, 31, 87
Behavioral sensitization, 279
2,3-Benzodiazepines, 595
Bicuculline methiodide, 573
Body weight, 433, 495
Brain, 199
Brain-stimulation reward, 297
Bromocriptine, 1
Butorphanol, 241, 343
BW534U87, 111

[¹¹C]raclopride, 425
Calcium, 389
Cannabinoid receptor, 31
Cannabinoids, 205
Carbamazepine, 221
Carbohydrate, 259
Cefoselis, 1, 53
Centella asiatica, 579
Central amygdala, 187
Cerebral cortex, 181
Cerebral ischemia, 481
CFM-2, 595
Charybdotoxin, 465
Chemoconvulsions, 595
Chromaperidine, 213
Chromaproline, 213
Chronic stress, 181
Citalopram, 95
Cocaine, 157, 173, 287, 297, 313, 449
Codling moth *Cydia pomonella*, 389
Conditioned place preference (CPP), 623

Conditioned place preference, 187, 363, 529, 617, 869
Conditioned test aversion, 869
Convulsion, 1, 53
Convulsions, 343, 523
Corticosterone, 433, 609
CP 55,940, 649
Cross-sensitization, 635

D₂ receptors, 335
DBA/2 mice, 595
Dependence, 129
Detection, 287
Dextromethorphan, 73, 313, 803
Diabetes, 1
5,7-dihydroxytryptamine, 587
Discrimination, 287
DOM, 95
DOPAC, 87
Dopamine, 1, 11, 21, 61, 425, 449, 529, 803, 827
Dopamine D₂ receptors, 187, 425
Dorsal raphe nucleus, 587
Drug abuse, 623
Drug discrimination, 95
Drug discrimination, (rat), 371
Drug reinforcement, 623
Drug reward, 623

EHNA, 111
EL mouse, 111
Electrical kindling, 111
Electroencephalogram, 141, 811
Electroencephalography (EEG), 513
Electroshock seizures, 795
Elevated plus-maze, 395
(-)-Ephedrine, 157
Epilepsy, 579, 595
Estradiol, 1, 381
Estradiol valerate, 381
Estrogen, 41, 173, 229, 381, 471
Ethanol, 41, 229, 381, 471, 869
Excitatory amino acids, 455
Exercise, 357

- Fatigue, 357
 Fear, 395
 Feeding, 389, 417
 Female subjects, 173
 Females, 325
 Fentanyl, 73, 529
 Flavor conditioning, 41, 229
 Flumazenil, 573
 Fluoxetine, 95
 Flurothyl, 141
 Focal cerebral ischemia, 663
 Food intake, 505
 Forelimb use, 663
 Formalin-induced tonic pain, 199
 Fos, 657
 Free-operant avoidance, 221
 β -funaltrexamine, 617

 GABA, 1, 53, 141
 GABA_A receptor, 573
 GABA γ -aminobutyric acid, 53
 Gabapentin, 565
 Gamma aminobutyric acid, 523
 Gastric infusions, 41, 229
 Gender differences in self-administration, 541
 Genetics, 471
 Glibenclamide, 465
 Glutamate, 21
 Glutamate receptor, 389
 Glutamate receptor antagonists, 455
 Glutamine, 523
 [³H] Glycine efflux, 811
 [³H] Glycine uptake, 811
 Grooming, 827
 GSHglutathione, 641
 GYKI 52466, 595
 GYKI 53655, 595
 GYKI 53773, 595

 Hallucinogens, 95
 Haloperidol, 1, 641
 Helplessness, 269
 Heroin, gender differences, 541
 Heroin, self-administration, 541
 Hippocampus, 149, 411, 455, 587
 Histamine H₁ receptor, 487
 Horizontal activity, 325
 Hot-plate, 73
 5-HT receptor subtypes, 559
 5-HT_{1A} receptors, 335
 5-HT₃ receptors, 297
 Hyperlocomotion, 869
 Hyperphagia, 495
 Hypophagia, 495

 Hypothalamus, 181
 Hypoxia, 303

 Identification, 287
 Immobilization, 325
 In vivo binding, 425
 In vivo microdialysis, 21, 609
 Indorenate, 371
 Infection, 433
 Inflammation, 433
 Inhalant, 623
 Insects, 389

 K⁺ channels, 465
 Kainate, 389
 Ketamine, 73
 Kindling, 579

 L-type channel, 269
 Lactation, 11
 Lamotrigine, 565
 Learning, 119, 129, 395, 579
 Lesch–Nyhan disease, 1, 61
 Lever release, 287
 Lick microstructure, 163
 Lipid, 259
 Lipopolysaccharide, 505
 Lobeline, 279
 Locomotion, 87
 Locomotor activity, 31, 279, 313, 325, 617
 Long–Evans, 325
 Long–Evans rats, 129

 M₁ receptor, 411
 M₄ receptor, 411
 Males, 325
 Maltodextrin, 41
 Maternal aggression, 449
 Maternal behavior, 11
 Maximal electroshock, 343, 595
 Maximal electroshock seizure, 111
 Meal number, 495
 Meal size, 495
 Mecamylamine, 363
 Mechanical efficiency, 357
 α -Melanocyte-stimulating hormone, 417
 Melatonin, 573, 641
 Memory, 411
 Menopause, 1
 Met-enkephalin, 1
 Metabolic rate, 357
 Metabolism, 87
 Metamizol, 465
 Methcathinone, 157

 α -Methyl-*para*-tyrosine, 425
 Methylphenidate, 157
 Mice, 1, 53, 73, 795
 Microdialysis, 61, 587, 803
 Midazolam, 395
 MK-801, 303, 351, 565, 833
 Modulation, 551
 Mongolian gerbils, 141
 Monoamines, 609
 Mood, 513
 Morphine, 73, 187, 363, 617, 795, 803
 Morphine, gender differences, 541
 Morphine, self-administration, 541
 Mouse, 111, 869
 Mouse strains, 351
 Mu-opioid agonists, 529
 Muscarinic acetylcholine receptor, 411
 Muscarinic toxins, 411

 Naloxonazine, 617, 795
 Naloxone, 129, 363, 551
 Naltrexone, 129
 Narcotic, 551
Nardostachys jatamansi, 481
 NBQX, 303, 595
 Negative reinforcement, 221
 Negative symptoms of schizophrenia, 811
 Neonatal 6-OHDA, 61
 Neuro behaviour, 481
 Neurodegeneration, 455
 Neuroleptic, 11
 Neuropeptide Y, 417
 Neuroprotection, 481
 Neurosteroid, 119
 NFPS, 811
 Nicotine, 279, 325, 363, 513
 Nicotine metabolite, 87
 Nicotinic agonists, 213
 Nimodipine, 269
 Nitric oxide, 149, 795
 Nitric oxide synthase inhibitors, 795
 NK₁ receptor, 487
 NMDA, 53, 313, 389
 NMDA receptor, 351, 551
N-Methyl-D-aspartate, 343
 Nociceptin, 657
 Nociception, 73
 Nociceptive response, 1, 487
 Nongenomic, 119
 Nor-binaltorphimine, 241
 NSAID, 603
 Nucleotide hydrolysis, 181
 Nucleus accumbens, 21, 803
 Nucleus paragigantocellularis, 241
 Nursing, 11

- Object recognition memory, 213
 Obsessive–compulsive disorder, 559
 Open-field, 433
 Operant behavior, 221
 Operant therapy, 1, 61
 Operant training, 1, 61
 Opiate reward, 617
 Opiates, gender differences, 541
 κ -Opioid receptor, 241
 μ -Opioid receptors, 617
 Opioids, 343, 551
 Oral contraceptives, 173
 Oral habituation, 163
 Org 24461, 811
 ORL1 receptors, 657
 Ovariectomy, 1
 Oxidative stress, 481, 641
- Palatability, 163
 Passive avoidance, 579
 Paternal behavior, 11
 PCGpenicillin G, 53
 PCP, 313
 Periadolescence, 335
 Phencyclidine, 351
 Picrotoxin, 573
 Pilocarpine, 205
 Place conditioning, 623
 Positive reinforcement, 119, 221
 Positron emission tomography, 425
 Prepulse inhibition, 1
 Progesterone, 173
 Protein, 259
 Psychological stress, 401
 PTZ, 111, 579
- Quinpirole, 1, 187, 827
- R*(–)Methamphetamine, 157
 Rat, 95, 111, 187, 199, 221, 279, 417, 587, 657, 663
 Rat blood serum, 181
 Rats, 269, 579
 Reaction time, 287
 Recovery, 663
 5 α -Reductase, 199
 Repeated acquisition, 129
 Restraint stress, 149
- Reward, 119, 529, 869
 Ritanserin, 505
- S*(+)Amphetamine, 157
S(+)Methamphetamine, 157
 Saccharin, 229
 SB 242084, 505
 SCH23390, 833
 Schizophrenia, 351
 Scorpion toxins, 455
 Seizure models, 111
 Seizures, 303, 313
 Selective κ -, μ - and δ -opioid antagonists, 649
 Selectively bred rats, 827
 Self-administration, 541
 Self-injurious behavior, 1, 61
 Sensitization, 87, 803
 Sensorimotor, 663
 SERMs, 381
 Serotonin, 449, 505, 513, 559, 587
 Serotonin receptors, 371
 Serum, 199
 Sex differences, 11, 325
 Sex hormones, 433
 Sickness behavior, 433
 Sigma-1, 313
 Sigma₁ (σ_1) receptor, 869
 SKF 38393, 827
 Sleep, 573
 Smokers, 401
 Smoking, 495, 513
 Smoking withdrawal, 513
 SNC80, 73
 SODsuperoxide dismutase, 641
 Spatial memory, 213
 Spinal cord, 199, 657
 Spleen weight, 433
 Spontaneous alternation behavior, 559
 Spontaneous stereotypy, 833
 Sprague–Dawley, 325
 SR-141716A, 31
 SR141716A, 129
 SR141716A*N*-(piperidin-1-yn-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole-3-carboxamide hydrochloride, 129
 SSRIs, 95
 Stimulation, 31
- Strain differences, 325
 Stress, 269, 609
 Stress-induced analgesia, 149
 Striatum, 1, 61, 833
 Substance P, 487
 Sucrose+saccharin, 163
 Sucrose, 529, 635
 Sufentanil, 73
 Sugar, 635
 Sulpiride, 187
 Synthesis, 87
- Tail-flick, 149
 Tail-flick test, 603
 Tardive dyskinesia, 641
 Taurine, 21
 Testosterone, 199
 Tetraethylammonium, 465
 Δ^8 -THC, 205
 Δ^9 -THC, 129, 205
 Δ^9 -THC Δ^9 -tetrahydrocannabinol, 129
 Thigmotaxis, 433
 Tobacco alkaloid, 87
 Tolbutamide, 465
 Tolerance, 87, 129, 363, 471, 565
 Tonic extension, 141
 Tryptophan, 357, 513
- U50,488H, 73
- Variable interval schedule, 221
 VCMs, 641
 VCMsvacuous chewing movements, 641
 Vertical activity, 325
 Vicarious trial and error, 559
 Voles, 11
- Water intake, 495
 Withdrawal, 551
- X-maze, 587
- Y-25130, 297
 Yawning, 205, 827
- Zebrafish, 471